2'-O-methyl and 2'-O-ethyl modified oligoribonucleotides are potent, nuclease-resistant inhibitors of U7 snRNP-dependent mRNA processing in vitro.
Modified antisense oligos enable stable in vitro mRNA inhibition; leaves open in vivo efficacy and therapeutic translation.
We describe the synthesis of 2'-O-methyl, 2'-O-ethyl oligoribonucleotides and phosphorothioate oligodeoxyribonucleotides and demonstrate their utility as inhibitors of the in vitro U7 snRNP-dependent mRNA processing event. These 2'-O-modified compounds were designed to possess the binding affinity of an RNA molecule towards a complementary RNA target with an enhanced stability against nucleases. The 2'-O-methyl and 2'-O-ethyl antisense compounds function as potent inhibitors of the reaction at 1-10 nM, approximately 5-fold more effective than a natural antisense RNA molecule and requiring an approximate 5-fold excess over the target RNA for 80% inhibition of the processing reaction.
No takes yet. Share an insight, caveat, or question.
Cotten et al. (1991) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: